Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE)(7m)-β-CD

Pharmaceutical Research

Volumn 16, Issue 4, 1999, Pages 549-554

  Okimoto, Kazuto ^a   Ohike, Atsuo ^a   Ibuki, Rinta ^a   Aoki, Osamu ^a   Ohnishi, Norio ^a   Irie, Tetsumi ^b   Uekama, Kaneto ^b   Rajewski, Roger A ^c   Stella, Valentino J ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

(SBE)(7m) CD; Controlled porosity osmotic pump tablet; Cyclodextrins; HP CD; Osmotic pump

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CHLORPROMAZINE; LACTOSE; SUCROSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG RELEASE; DRUG SOLUBILITY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; OSMOTIC PUMP; PRIORITY JOURNAL; TABLET; TABLET MACHINE; TABLET MANUFACTURE;

EID: 0032956350     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018827214223     Document Type: Article

References (25)

1. 1. R. S. Langer and D. L. Wise (Ed.). Medical applications of controlled release. Vol. I, II, CRC Press, Inc., Boca Raton (1984).
2. 2. L. Hendeles, R. P. Iafrate, and M. Weinberger. A clinical and pharmacokinetics basis for the selection and use of slow release theophylline products. Clin. Pharmacokin. 9:95-135 (1984).
3. 3. R. G. Shanks. In rate control in drug therapy. L. F. Prescott and W. S. Nimmo (Ed.), Churehill Livingstone, Edinburgh (1985).
4. 4. V. A. John. Proceedings of the First European Congress of Biopharmaceutics and Pharmacokinetics. Vol. I: J. M. Aiache and J. Hirtz (Ed.), Paris Technique et Documentation (1981).
5. 5. F. Theeuwes. Elementary osmotic pump. J. Pharm. Sci. 64: 1987-1991 (1975).
6. 6. B. Eckenhoff, F. Theeuwes, and J. Urquhart. Osmotically actuated dosage forms for rate-controlled drug delivery. Pharm. Techn. 5:35-44 (1981).
7. 7. G. M. Zentner, G. S. Rork, and K. J. Himmelstein. Osmotic flow through controlled porosity films: An approach to delivery of water soluble compounds. J. Contr. Rel. 2:217-229 (1985).
8. 8. G. M. Zentner and G. S. Rork. Controlled porosity osmotic pump. U.S. Patent 4, 968, 507 (1990).
9. 7m-β-CD as both a solubilizing and osmotic agent. J. Contr. Rel. (in press).
10. 7m-β-CD. Pharm. Res. 10:1562-1567 (1998).
11. 11. J. S. Grundy, K. E. Anderson, J. A. Rogers, and R. T. Foster. Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. II. Improved in vitro-in vivo correlation usinga two-phase dissolution test. J. Contr. Rel. 48:9-17 (1997).
12. 12. F. Theeuwes and T. Higuchi. Osmotic dispersing device for releasing beneficial agent. U.S. Patent 3, 845, 770, November 5, 1974.
13. 13. M. J. Kendall, D. B. Jack, K. L. Woods, S. J. Laugher, C. P. Quaterman, and V. A. John. Comparison of the pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros® delivery systen. Br. J. Clin. Pharmacol. 13:393-398 (1982).
14. 14. G. M. Zentner, G. A. McClelland, and S. C. Sutton. Controlled porosity solubility-and resin-modulated osmotic drug delivery systems for release of diltiazem hydrochloride. J. Contr. Rel. 16:237-244 (1991).
15. 15. R. Bodmeier and O. Paeratakul. Theophylline tablets coated with aqueous latexes containing dispersed pore formers. J. Pharm. Sci. 79:925-928 (1990).
16. 16. S. M. Herbig, J. R. Cardinal, R. W. Korsmeyer, and K. L. Smith. Asymmetric-membrane tablet coatings for osmotic drug delivery. J. Contr. Rel. 35:126-136 (1995).
17. 17. V. J. Stella and R. A. Rajewski. Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the pharmaceutical use thereof. U.S. Patent 5, 134, 127, July 18, 1992.
18. 18. K. Okimoto, R. A. Rajewski, K. Uekama, J. A. Jona, and V. J. Stella. The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE7-β-CD) β-cyclodextrins. Pharm. Res. 13:256-264 (1996).
19. 19. V. Zia, R. A. Rajewski, E. R. Bornancini, E. A. Luna, and V. J. Stella. Effect of alkyl chain length and degree of substitution on the complexation of sulfoalkyl ether β-cyclodextrins with steroids. J. Pharm. Sci. 86:220-224 (1997).
20. 20. T. Higuchi and K. Connors. Phase-solubility techniques, in: C. N. Reilly (Ed.), Advances in Analytical Chemistry and Instrumentation, Interscience, New York, 1965, pp. 117-212.
21. 21. J. P. Skelly. Controlled drug delivery. J. R. Robinson and V. H. Lee (Ed.), Marcel Dekker Inc., New York, 294 (1987).
22. 22. M. C. Meyer, A. B. Straughn, P. Lieberman, and J. Jacob. Serious bioavalability problems with a generic prolonged-release quinidine gluconate product. J. Clin. Pharmacol. 22:131-134 (1982).
23. 23. N. Aoyagi, H. Ogata, N. Kaniwa, and A. Ejima. Bioavailability of indomethacin capsules in humans (1): Bioavailability and effects of gastric acidity. Int. J. Clin. Pharmacol. Ther. Toxicol. 23:496-474 (1985).
24. 24. J. P. Skelly, G. L. Amidon, W. H. Barr, L. Z. Benet, J. R. Carter, J. R. Robinson, V. P. Shah, and A. Yacobi. In vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms. Pharm. Res. 7:975-982 (1990).
25. 25. J. G. Wagner. Application of the Loo-Riegelman absorption method. J. Pharmacokin. Biopharm. 3:51 (1975).